FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 953 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR El cáncer en mi comunidad: Cómo superar las desigualdades en la... January 3, 2023 ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland November 29, 2022 Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... May 22, 2024 Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... September 11, 2023 Load more HOT NEWS A New Era of Early Cancer Detection With Blood Test May... Using Technology to Find Cancers Early and Exercise Improves Sexual Health... FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include... Sex, intimacy and cancer – That Cancer Conversation
